KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt RepaymentsR&D In ProcessShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for Pfizer (PFE) over the last 17 years, with Q2 2025 value amounting to $3.8 billion.

  • Pfizer's Long-Term Debt Repayments rose 27500.0% to $3.8 billion in Q2 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year increase of 3333.33%. This contributed to the annual value of $2.2 billion for FY2024, which is 1241.73% down from last year.
  • According to the latest figures from Q2 2025, Pfizer's Long-Term Debt Repayments is $3.8 billion, which was up 27500.0% from $2.2 billion recorded in Q3 2024.
  • Over the past 5 years, Pfizer's Long-Term Debt Repayments peaked at $3.8 billion during Q2 2025, and registered a low of $269.0 million during Q2 2023.
  • For the 5-year period, Pfizer's Long-Term Debt Repayments averaged around $1.5 billion, with its median value being $1.3 billion (2023).
  • Per our database at Business Quant, Pfizer's Long-Term Debt Repayments plummeted by 8328.15% in 2023 and then surged by 36468.4% in 2024.
  • Quarter analysis of 5 years shows Pfizer's Long-Term Debt Repayments stood at $1.0 billion in 2021, then soared by 60.74% to $1.6 billion in 2022, then fell by 19.2% to $1.3 billion in 2023, then surged by 73.08% to $2.2 billion in 2024, then soared by 66.67% to $3.8 billion in 2025.
  • Its last three reported values are $3.8 billion in Q2 2025, $2.2 billion for Q3 2024, and $1.0 billion during Q2 2024.